SNS-314 MESYLATE

SNS-314 MESYLATE

Biochem/physiol Actions

SNS-314 is a potent pan-aurora kinases inhibitor (IC50 = 9/31/3 nM against aurora kinase A/B/C or aurora 2/1/3) that binds aurora kinase in the DFG-in conformation and exhibits great selectivity against a panel of 219 kinases (>5-, >12-, >14-, >15-, >82-, >84-fold selectivity for aurora A over TrkB, TrkA, Flt4, Fms, DDR2, Axl, respectively; >100-fold selectivity over c-Raf and the remaining kinases). SNS-314 downregulates cellular histone H3 Ser10 (HH3 Ser10) phosphorylation (IC50 ﹤16 nM) and exhibits potent antiproliferation activity in HCT116 human colon cancer cultures in vitro (IC50 = 5 nM). When applied in vivo, HCT116 likewise reduces pHH3 (Ser10) level in tumor tissue (by 75-100% 6 hrs post 50 mg/kg i.p. dosage) and suppresses tumor growth (100 mg/kg/day, 5 days on, 9 days off; 150 mg/kg biweekly x3), as well as potentiates docetaxel antitumor efficacy in a mouse HCT116 xenograft model in vivo (42.5 mg SNS-314/kg followed by 10 mg docetaxel/kg 24 hr later; biweekly x3).

Potent and selective pan-aurora kinase inhibitor that binds aurora kinase in the DFG-in conformation and exhibits anticancer efficacy in vitro and in vivo.

No detailed specifications are available for this product.

There are no downloads for this product.

Code Description Colour Manufacturer Storage Temp. Solubility Form Assay Price Quantity
3575940 SNS-314 MESYLATE white to beige SIGMA-ALDRICH −20°C DMSO: 2 mg/mL, clear
£360.05 (exc VAT) per 25MG
-
+
3575941 SNS-314 MESYLATE white to beige SIGMA-ALDRICH −20°C DMSO: 2 mg/mL, clear
£89.14 (exc VAT) per 5MG
-
+